Top

Published in:

Open Access 01-12-2015 | Erratum

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Authors: Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, Camilo Garcia, Marc Peeters, Lieven Annemans, Caroline Vandeputte, Marion Maetens, Marc Van den Eynde, Raphaël Maréchal, Ivan Borbath, Damien Dresse, Ghislain Houbiers, Michael Fried, Ahmad Awada, Martine Piccart, Jean-Luc Van Laethem, Patrick Flamen

Published in: BMC Cancer | Issue 1/2015

Excerpt

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. The full list of authors and the corrected Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused. …

Alain H, Vassilis G, Amelie D, Marianne P, Hazem El M, Camilo G, et al. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer. 2013;13:190.CrossRef

Title: Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
Authors: Alain Hendlisz
Vassilis Golfinopoulos
Amelie Deleporte
Marianne Paesmans
Hazem El Mansy
Camilo Garcia
Marc Peeters
Lieven Annemans
Caroline Vandeputte
Marion Maetens
Marc Van den Eynde
Raphaël Maréchal
Ivan Borbath
Damien Dresse
Ghislain Houbiers
Michael Fried
Ahmad Awada
Martine Piccart
Jean-Luc Van Laethem
Patrick Flamen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1181-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening

Inter-observer agreement according to three methods of evaluating mammographic density and parenchymal pattern in a case control study: impact on relative risk of breast cancer

Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer